Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: Historical comparison between two phase 3 trials

Lydia Roy, Joëlle Guilhot, Tillmann Krahnke, Agnès Guerci-Bresler, Brian Druker, Richard A. Larson, Steve O'Brien, Charlene So, Giorgio Massimini, François Guilhot

Research output: Contribution to journalArticle

180 Citations (Scopus)

Abstract

In the multinational IRIS study comparing imatinib with interferon plus cytarabine (IFN/Ara-C) in patients with newly diagnosed chronic-phase chronic myelogenous leukemia (CP CML), imatinib demonstrated significantly higher rates of complete cytogenetic responses (CCyRs) and improved progression-free survival (PFS). However, because of a high early crossover rate to imatinib, survival benefit was not assessable. Here, we report the result of a study comparing long-term outcome of patients included in 2 prospective randomized trials: 551 patients assigned to imatinib in the IRIS trial from 2000 to 2001 and 325 patients who received the combination IFN/Ara-C in the CML91 trial between 1991 and 1996 before imatinib was available. With a follow-up of 42 months for both groups of patients, estimated CCyR, survival free of transformation, and overall survival were significantly higher with imatinib compared with IFN/Ara-C (P <.001, P = .004, and P <.001, respectively). Improved overall survival was also confirmed within different Sokal prognostic risk groups. Of interest, among all patients who achieved major cytogenetic response or CCyR at 12 months, the survival rate was similar irrespective of their treatment. In conclusion, within the limitation of this historical comparison, there is a survival advantage from first-line therapy with imatinib over IFN/Ara-C.

Original languageEnglish (US)
Pages (from-to)1478-1484
Number of pages7
JournalBlood
Volume108
Issue number5
DOIs
StatePublished - Sep 1 2006
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Cytarabine
Interferons
Survival
Cytogenetics
Imatinib Mesylate
Disease-Free Survival
Survival Rate
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia : Historical comparison between two phase 3 trials. / Roy, Lydia; Guilhot, Joëlle; Krahnke, Tillmann; Guerci-Bresler, Agnès; Druker, Brian; Larson, Richard A.; O'Brien, Steve; So, Charlene; Massimini, Giorgio; Guilhot, François.

In: Blood, Vol. 108, No. 5, 01.09.2006, p. 1478-1484.

Research output: Contribution to journalArticle

Roy, Lydia ; Guilhot, Joëlle ; Krahnke, Tillmann ; Guerci-Bresler, Agnès ; Druker, Brian ; Larson, Richard A. ; O'Brien, Steve ; So, Charlene ; Massimini, Giorgio ; Guilhot, François. / Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia : Historical comparison between two phase 3 trials. In: Blood. 2006 ; Vol. 108, No. 5. pp. 1478-1484.
@article{7446b1e68c19453a842aa84a9ba1504b,
title = "Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: Historical comparison between two phase 3 trials",
abstract = "In the multinational IRIS study comparing imatinib with interferon plus cytarabine (IFN/Ara-C) in patients with newly diagnosed chronic-phase chronic myelogenous leukemia (CP CML), imatinib demonstrated significantly higher rates of complete cytogenetic responses (CCyRs) and improved progression-free survival (PFS). However, because of a high early crossover rate to imatinib, survival benefit was not assessable. Here, we report the result of a study comparing long-term outcome of patients included in 2 prospective randomized trials: 551 patients assigned to imatinib in the IRIS trial from 2000 to 2001 and 325 patients who received the combination IFN/Ara-C in the CML91 trial between 1991 and 1996 before imatinib was available. With a follow-up of 42 months for both groups of patients, estimated CCyR, survival free of transformation, and overall survival were significantly higher with imatinib compared with IFN/Ara-C (P <.001, P = .004, and P <.001, respectively). Improved overall survival was also confirmed within different Sokal prognostic risk groups. Of interest, among all patients who achieved major cytogenetic response or CCyR at 12 months, the survival rate was similar irrespective of their treatment. In conclusion, within the limitation of this historical comparison, there is a survival advantage from first-line therapy with imatinib over IFN/Ara-C.",
author = "Lydia Roy and Jo{\"e}lle Guilhot and Tillmann Krahnke and Agn{\`e}s Guerci-Bresler and Brian Druker and Larson, {Richard A.} and Steve O'Brien and Charlene So and Giorgio Massimini and Fran{\cc}ois Guilhot",
year = "2006",
month = "9",
day = "1",
doi = "10.1182/blood-2006-02-001495",
language = "English (US)",
volume = "108",
pages = "1478--1484",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia

T2 - Historical comparison between two phase 3 trials

AU - Roy, Lydia

AU - Guilhot, Joëlle

AU - Krahnke, Tillmann

AU - Guerci-Bresler, Agnès

AU - Druker, Brian

AU - Larson, Richard A.

AU - O'Brien, Steve

AU - So, Charlene

AU - Massimini, Giorgio

AU - Guilhot, François

PY - 2006/9/1

Y1 - 2006/9/1

N2 - In the multinational IRIS study comparing imatinib with interferon plus cytarabine (IFN/Ara-C) in patients with newly diagnosed chronic-phase chronic myelogenous leukemia (CP CML), imatinib demonstrated significantly higher rates of complete cytogenetic responses (CCyRs) and improved progression-free survival (PFS). However, because of a high early crossover rate to imatinib, survival benefit was not assessable. Here, we report the result of a study comparing long-term outcome of patients included in 2 prospective randomized trials: 551 patients assigned to imatinib in the IRIS trial from 2000 to 2001 and 325 patients who received the combination IFN/Ara-C in the CML91 trial between 1991 and 1996 before imatinib was available. With a follow-up of 42 months for both groups of patients, estimated CCyR, survival free of transformation, and overall survival were significantly higher with imatinib compared with IFN/Ara-C (P <.001, P = .004, and P <.001, respectively). Improved overall survival was also confirmed within different Sokal prognostic risk groups. Of interest, among all patients who achieved major cytogenetic response or CCyR at 12 months, the survival rate was similar irrespective of their treatment. In conclusion, within the limitation of this historical comparison, there is a survival advantage from first-line therapy with imatinib over IFN/Ara-C.

AB - In the multinational IRIS study comparing imatinib with interferon plus cytarabine (IFN/Ara-C) in patients with newly diagnosed chronic-phase chronic myelogenous leukemia (CP CML), imatinib demonstrated significantly higher rates of complete cytogenetic responses (CCyRs) and improved progression-free survival (PFS). However, because of a high early crossover rate to imatinib, survival benefit was not assessable. Here, we report the result of a study comparing long-term outcome of patients included in 2 prospective randomized trials: 551 patients assigned to imatinib in the IRIS trial from 2000 to 2001 and 325 patients who received the combination IFN/Ara-C in the CML91 trial between 1991 and 1996 before imatinib was available. With a follow-up of 42 months for both groups of patients, estimated CCyR, survival free of transformation, and overall survival were significantly higher with imatinib compared with IFN/Ara-C (P <.001, P = .004, and P <.001, respectively). Improved overall survival was also confirmed within different Sokal prognostic risk groups. Of interest, among all patients who achieved major cytogenetic response or CCyR at 12 months, the survival rate was similar irrespective of their treatment. In conclusion, within the limitation of this historical comparison, there is a survival advantage from first-line therapy with imatinib over IFN/Ara-C.

UR - http://www.scopus.com/inward/record.url?scp=33748133844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748133844&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-02-001495

DO - 10.1182/blood-2006-02-001495

M3 - Article

C2 - 16627756

AN - SCOPUS:33748133844

VL - 108

SP - 1478

EP - 1484

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -